Get the Stockscreener App
3.0082
6.43%
-0.2068
After Hours:
3.01
0.0018
+0.06%
Ezfill Holdings Inc stock is traded at $3.0082, with a volume of 16,510.
It is down -6.43% in the last 24 hours and up +1.63% over the past month.
EzFill Holdings Inc is an application-based on-demand fuel delivery company in Florida and a mobile fueling company that combines on-demand fills and subscription services that fill customer vehicles on routine intervals. It provides fuel-delivery on-demand or in subscription to fill customer vehicles on routine intervals for the consumer, fleet, marine, and other specialty markets. EzFill's app-based platform brings the gas station to customers with a growing fleet of EzFill-branded, Mobile Fueling Trucks. The company provides gas delivery via Mobile Fueling Trucks in the greater South Florida area as well as in the West Palm Beach, Jacksonville, Tampa, and Orlando areas, and expects to soon begin fueling in other areas in Florida.
See More
Previous Close:
$3.215
Open:
$3.4217
24h Volume:
16,510
Relative Volume:
0.78
Market Cap:
$18.68M
Revenue:
$22.38M
Net Income/Loss:
$-13.33M
P/E Ratio:
-0.6641
EPS:
-4.53
Net Cash Flow:
$-8.06M
1W Performance:
-11.78%
1M Performance:
+1.63%
6M Performance:
-29.63%
1Y Performance:
-55.28%
1-Day Range:
$2.90
$3.4217
1-Week Range:
$2.90
$4.00
52-Week Range:
$2.36
$7.5498
Ezfill Holdings Inc Stock (EZFL) Company Profile
Name
Ezfill Holdings Inc
Sector
Industry
Phone
305-791-1169
Address
67 NW 183RD ST, MIAMI
Ezfill Holdings Inc Stock (EZFL) Latest News
EzFill Holdings revises share exchange in NextNRG acquisition - Investing.com
EzFill Holdings revises share exchange in NextNRG acquisition By Investing.com - Investing.com Canada
EzFill Holdings revises share exchange in NextNRG acquisition By Investing.com - Investing.com UK
EZFill Holdings Inc. (NASDAQ:EZFL) Short Interest Down 56.5% in September - Defense World
FDA Approves Miplyffa for Niemann-Pick Disease, Type C - MyChesCo
FDA Approves Miplyffa for Ultra Rare Niemann-Pick Disease Type C - Managed Healthcare Executive
FDA approves Zevra’s Miplyffa for Niemann-Pick disease type C treatment - World Pharmaceutical Frontiers
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 By Investing.com - Investing.com South Africa
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 By Investing.com - Investing.com Australia
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 By Investing.com - Investing.com Canada
EzFill holdings CTO Avishai Vaknin sells shares worth $2300 - Investing.com
Ezzaty Abdullah admits to be delivering her baby soon - Yahoo Lifestyle Singapore
FDA approves Zevra Therapeutics’ Miplyffa for Niemann-Pick disease - Pharmaceutical Technology
FDA clears first drug for Niemann-Pick disease - pharmaphorum
Zevra’s Miplyffa wins first FDA approval in Niemann-Pick type C - BioWorld Online
EzFill Holdings (NASDAQ:EZFL) Stock Quotes, Forecast and News Summary - Benzinga
After prior snub, Zevra clinches FDA approval for rare lysosomal storage disorder drug Miplyffa - FiercePharma
First Drug Approved for Niemann-Pick Disease Type C - Medpage Today
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease - Benzinga
Arimoclomol Becomes First FDA Approved Treatment for Neimann-Pick Disease Type C - Pharmacy Times
FDA approves first Niemann-Pick disease, type C treatment - The Pharma Letter
FDA approves arimoclomol as first drug to treat Neimann-Pick disease, type C - Contemporary Pediatrics
EZFill Holdings Inc. (NASDAQ:EZFL) CTO Sells $20,550.00 in Stock - Defense World
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k By Investing.com - Investing.com South Africa
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k - Investing.com India
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k - Investing.com
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k - Investing.com Canada
EzFill holdings CTO Avishai Vaknin sells shares worth nearly $30k - Investing.com UK
Extra Storage rises on Jefferies upgrade - XM
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 By Investing.com - Investing.com Australia
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 - Investing.com
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 By Investing.com - Investing.com Canada
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 - Investing.com India
EzFill holdings CTO Avishai Vaknin sells shares worth $29,180 By Investing.com - Investing.com UK
Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article - Morningstar
Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss - MarketWatch
FDA Approves Eli Lilly's Drug for Eczema - Newsmax
Insider Sale: CTO Avishai Vaknin Sells Shares of EzFill Holdings Inc (EZFL) By GuruFocus - Investing.com Canada
EzFill Holdings CTO Avishai Vaknin sells $74,862 in company stock By Investing.com - Investing.com Canada
EzFill Holdings CTO Avishai Vaknin sells $74,862 in company stock - Investing.com
EzFill holdings CTO Avishai Vaknin sells shares worth over $15k - Investing.com
EzFill holdings CTO Avishai Vaknin sells shares worth over $15k - Investing.com India
EzFill regains compliance with Nasdaq's equity rule - Investing.com
EzFill Holdings Regains Nasdaq Compliance, Faces Monitoring - TipRanks
EzFill Holdings, Inc. Regains Compliance with NASDAQ Listing Standard - GlobeNewswire
EzFill Holdings, Inc. Regains Compliance with NASDAQ Listing Standard - StockTitan
EzFill Holdings Inc’s latest rating changes from various analysts - Knox Daily
Daily Market Movement: EzFill Holdings Inc (EZFL) Sees a -3.27 Decrease, Closing at 2.96 - The Dwinnex
EZFill Holdings Inc. (NASDAQ:EZFL) Short Interest Update - Defense World
EZFL: Synergies of Pending Merger; Balance Sheet Measures Expected to Reduce Debt, Interest Expense & Regain Nasdaq Compliance… - MSN
An Analysis of EzFill Holdings Inc (EZFL)’s Potential Price Growth - Knox Daily
Ezfill Holdings Inc Stock (EZFL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.32%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):